KCTD18

Across TCGA pan-cancer cohorts, KCTD18 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated KCTD18 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher KCTD18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KCTD18 expression acts as an unfavorable survival marker.

OV, KIRC, and GBM are the cancer types where KCTD18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.180	0.844	<.001	36	view →
KIRC	OS	Median	All	0.125	0.881	<.001	12	view →
GBM	OS	Median	All	0.005	0.416	<.001	12	view →
LUSC	OS	Median	III,IV	0.112	0.664	.012	12	view →
UCEC	OS	Median	IV	0.259	0.770	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	III,IV	0.170	0.697	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

KCTD18–OV (OS)

Open the OV breakdown →